Last reviewed · How we verify

Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Dose and Food Interaction Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Male Subjects

NCT02099071 Phase 1 COMPLETED

This is a prospective, single-center, double-blind, randomized, placebo-controlled, ascending single oral dose and food interaction Phase 1 study. It will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single oral doses of ACT-389949 in healthy male subjects. It will also investigate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose of ACT-389949.

Details

Lead sponsorIdorsia Pharmaceuticals Ltd.
PhasePhase 1
StatusCOMPLETED
Enrolment65
Start date2011-11
Completion2012-05

Conditions

Interventions

Primary outcomes

Countries

Netherlands